Membership
Harvard Cancer Consortium (HCC) membership grants access to Consortium-sponsored core facilities at a reduced rate, clinical research support for protocol management, and members-only developmental funding opportunities. The Consortium promotes opportunities for collaboration among members through Program retreats, symposia, and publications and communications highlighting research and news across HCC.
Harvard Cancer Consortium (HCC) is a research consortium of more than 1,100 cancer researchers across five Boston academic medical institutions and two Harvard Schools. HCC, an NCI-Designated Comprehensive Cancer Center funded through a Cancer Center Support Grant awarded by the NCI, is one of the largest cancer research consortia in the country.
Learn more about our member institutions
- Beth Israel Deaconess Medical Center(opens in new window)
- Boston Children’s Hospital(opens in new window)
- Brigham and Women’s Hospital(opens in new window)
- Dana-Farber Cancer Institute(opens in new window)
- Massachusetts General Hospital(opens in new window)
- Harvard Medical School(opens in new window)
- Harvard T.H. Chan School of Public Health(opens in new window)
Responsibilities of members include active participation in a HCC program, adherence to the HCC Protocol Review and Monitoring System for the creation and implementation of all HCC-sponsored clinical cancer research, and acknowledgement of use of Cancer Center shared resources on research publications.
Both the NCI and HCC consider membership in a cancer center a privilege, and take very seriously the approval review processes for membership. Every three years, HCC membership status is reviewed. Program leaders conduct annual reviews of program membership to determine which individuals should and should not continue as program members based upon contributions to and participation in the activities and research.